|Bid||40.57 x 800|
|Ask||40.67 x 800|
|Day's Range||39.94 - 40.97|
|52 Week Range||38.06 - 61.08|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||74.07|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.67|
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Today we are going to look at Surmodics, Inc. (NASDAQ:SRDX) to see whether it might be an attractive investment...
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food and Drug Administration (FDA) has designated its Sundance™ sirolimus-coated balloon (SCB) catheter as a Breakthrough Device under the Agency’s Breakthrough Devices Program.
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2019 conference call on Thursday, October 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the fourth quarter fiscal 2019 financial results and provide fiscal 2020 revenue and EPS guidance.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
How far off is Surmodics, Inc. (NASDAQ:SRDX) from its intrinsic value? Using the most recent financial data, we'll...